EDMONTON, March 26, 2012 /CNW/ - Medwell Capital Corp. (TSXV: MWC) today announced the appointment of Tami Reich, CMA, to the position of Chief Financial Officer. Ms. Reich will take over from Brent Johnston as CFO on April 2, 2012.
Ms. Reich was most recently the Chief Operating Officer at BAMM Ventures Inc. (BAMM), an Edmonton-based venture capital firm where she oversaw a staff of over 60 people and offices throughout Alberta. Over the course of her career, she has also founded and operated two separate accounting firms focused on advising small to mid-sized businesses.
"We are pleased to welcome Tami to the Medwell team as we advance our portfolio of late stage healthcare investments and search for undervalued opportunities in the sector," said Kevin Giese, President and CEO of Medwell. "Her experience in a venture capital setting and her entrepreneurial background bring a valuable body of knowledge to our group. Brent fulfilled the CFO role at Medwell during an important period of transition. We thank him sincerely for the time he has been with us and for his support."
Brent Johnston joined Medwell Capital as CFO in 2008 and was active in guiding the Company through its evolution into a diversified investment and advisory firm. He is leaving to pursue other opportunities.
About Medwell Capital Corp.
Medwell Capital Corp. is a Canadian-based investment and and advisory firm. For further information please visit www.medwellcapital.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Corporation's ongoing quarterly and annual reporting. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
Medwell Capital Corp.
E-mail: [email protected]
416-815-0700 ext. 238